Cargando…

Economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015: a retrospective review of data from the regulatory authority

OBJECTIVE: To estimate the economic cost of substandard and falsified human medicines and cosmetics with banned ingredients in Tanzania from 2005 to 2015. DESIGN: A retrospective review of data. SETTING: Tanzania Food and Drugs Authority and premises dealing with importations and distributions of ph...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mori, Amani Thomas, Meena, Estella, Kaale, Eliangiringa A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Health Economics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6020956/ https://www.ncbi.nlm.nih.gov/pubmed/29950474 http://dx.doi.org/10.1136/bmjopen-2018-021825

Ejemplares similares

Substandard and Falsified Medicines in Myanmar
por: Sakuda, Mirai, et al.
Publicado: (2020)

Improved knowledge on substandard and falsified (SF) medical products through a dedicated course for pharmacy students at three universities in sub-Saharan Africa
por: Kusynová, Zuzana, et al.
Publicado: (2023)

Combatting Substandard and Falsified Medicines: A View from Rwanda
por: Binagwaho, Agnes, et al.
Publicado: (2013)

Quantitative screening of the pharmaceutical ingredient for the rapid identification of substandard and falsified medicines using reflectance infrared spectroscopy
por: Lawson, Graham, et al.
Publicado: (2018)

Priority setting for the implementation of artemisinin-based combination therapy policy in Tanzania: evaluation against the accountability for reasonableness framework
por: Mori, Amani Thomas, et al.
Publicado: (2012)

The economic impact of substandard and falsified antimalarial medications in Nigeria
por: Beargie, Sarah M., et al.
Publicado: (2019)

Substandard and falsified antibiotics: neglected drivers of antimicrobial resistance?
por: Zabala, Guillermo A, et al.
Publicado: (2022)

The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists
por: Ferrario, Alessandra, et al.
Publicado: (2019)

Substandard, falsified and unregistered medicines in Latin America, 2017-2018
por: Rojas-Cortés, Robin
Publicado: (2020)

Impact of substandard and falsified antimalarials in Zambia: application of the SAFARI model
por: Jackson, Kathryn D., et al.
Publicado: (2020)

Reforms: a quest for efficiency or an opportunity for vested interests’? a case study of pharmaceutical policy reforms in Tanzania
por: Mori, Amani Thomas, et al.
Publicado: (2013)

Technologies for Detecting Falsified and Substandard Drugs in Low and Middle-Income Countries
por: Kovacs, Stephanie, et al.
Publicado: (2014)

A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR
por: Tabernero, Patricia, et al.
Publicado: (2022)

Substandard and falsified medical products: bibliometric analysis and mapping of scientific research
por: Sweileh, Waleed M.
Publicado: (2021)

Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications
por: El-Dahiyat, Faris, et al.
Publicado: (2021)

Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance
por: Pisani, Elizabeth, et al.
Publicado: (2021)

Mobile apps for detecting falsified and substandard drugs: A systematic review
por: Ciapponi, Agustín, et al.
Publicado: (2021)

Falsified and substandard medicines trafficking: A wakeup call for the African continent
por: Wada, Yusuf Hassan, et al.
Publicado: (2022)

The uncertain role of substandard and falsified medicines in the emergence and spread of antimicrobial resistance
por: Cavany, Sean, et al.
Publicado: (2023)

Evaluating Low-Cost Optical Spectrometers for the Detection of Simulated Substandard and Falsified Medicines
por: Wang, Wenbo, et al.
Publicado: (2019)

Falsified and substandard cardiovascular drugs in Africa: a need for continued monitoring strategies
por: Antignac, Marie, et al.
Publicado: (2019)

The scourge of substandard and falsified medical products gets worse with COVID-19 pandemic
por: Shiferie, Fisseha, et al.
Publicado: (2020)

Tackling the global impact of substandard and falsified and unregistered/unlicensed anti-tuberculosis medicines
por: Akpobolokemi, Tamara, et al.
Publicado: (2022)

Substandard and Falsified Medications: A Barrier to Global Health Equity Exemplified in Ecuador
por: Yakhkind, Aleksandra, et al.
Publicado: (2022)

The Role of Evidence in the Decision-Making Process of Selecting Essential Medicines in Developing Countries: The Case of Tanzania
por: Mori, Amani Thomas, et al.
Publicado: (2014)

Substandard and falsified medical product recalls in Zambia from 2018 to 2021 and implications on the quality surveillance systems
por: Chabalenge, Billy, et al.
Publicado: (2022)

Can a Smartphone Application Help Address Barriers to Reporting Substandard/Falsified Medical Products? A Pilot Study in Tanzania and Indonesia
por: Wagnild, Janelle M., et al.
Publicado: (2023)

Substandard and falsified medicines in the UK: a retrospective review of drug alerts (2001–2011)
por: Almuzaini, Tariq, et al.
Publicado: (2013)

Blockchain Technology for Detecting Falsified and Substandard Drugs in Distribution: Pharmaceutical Supply Chain Intervention
por: Sylim, Patrick, et al.
Publicado: (2018)

Retracted and Republished: A random survey of the prevalence of falsified and substandard antibiotics in the Lao PDR
por: Tabernero, Patricia, et al.
Publicado: (2019)

Identification of Substandard and Falsified Medicines: Influence of Different Tolerance Limits and Use of Authenticity Inquiries
por: Hauk, Cathrin, et al.
Publicado: (2021)

A critical review on the availability of substandard and falsified medicines online: Incidence, challenges and perspectives
por: Ahmed, Jamee, et al.
Publicado: (2022)

Prevalence of substandard and falsified artemisinin-based combination antimalarial medicines on Bioko Island, Equatorial Guinea
por: Kaur, Harparkash, et al.
Publicado: (2017)

Future Information Technology Tools for Fighting Substandard and Falsified Medicines in Low- and Middle-Income Countries
por: Rasheed, Huma, et al.
Publicado: (2018)

The Epidemic of Substandard and Falsified Medications in Iraq: Evaluating the Effectiveness of National Pharmacovigilance Alerts to Community Pharmacies
por: Al-Jumaili, Ali Azeez, et al.
Publicado: (2021)

Modeling the Health and Economic Impact of Substandard and Falsified Medicines: A Review of Existing Models and Approaches
por: Ozawa, Sachiko, et al.
Publicado: (2022)

Comparing the return on investment of technologies to detect substandard and falsified amoxicillin: A Kenya case study
por: Higgins, Colleen R., et al.
Publicado: (2023)

The response to substandard and falsified medical products in francophone sub-Saharan African countries: weaknesses and opportunities
por: Macé, Cécile, et al.
Publicado: (2023)

A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the Better
por: Tabernero, Patricia, et al.
Publicado: (2015)

Development of an agent-based model to assess the impact of substandard and falsified anti-malarials: Uganda case study
por: Ozawa, Sachiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9i1c4cbtpe9443ionbfe999d36